Jiang Zhong Pharmaceutical (SHA:600750) posted net profit attributable to shareholders of 906.7 million yuan for 2025, up 15% from 788.2 million yuan a year earlier.
Earnings per share at the drug manufacturer came in at 1.43 yuan, compared with 1.25 yuan a year earlier, according to a Thursday filing by parent China Resources Pharmaceutical (HKG:3320) with the Hong Kong bourse.
Revenue fell 5% to 4.22 billion yuan from 4.44 billion yuan.
The unit proposed a cash dividend of 8.80 yuan per 10 shares, subject to shareholder approval.